

August 12, 2025

To,  
The Manager  
Dept of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400001

Dear Sir/Madam,

**Subject : Outcome of the Board Meeting, Un-Audited Standalone & Consolidated Financial Results for the First Quarter ended June 30, 2025**  
**Reference : Regulation 30/33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**  
**Scrip : 511509**

With reference to the above cited subject and our letter dated August 06, 2025, we bring to your kind notice that the Board of Directors of the Company at their meeting held today, i.e. Tuesday, August 12, 2025, *inter-alia*, transacted the following business:

1. Considered and approved the Un-Audited Standalone & Consolidated Financial Results of the Company for the first quarter ended June 30, 2025.
2. Allotted 13,33,332 (Thirteen Lakh Thirty-Three Thousand Three Hundred and Thirty-Two only) Equity Shares of Rs. 10/- each at the issue price of Rs. 45/- (premium of Rs. 35/- on each equity share) on conversion of warrants issued on preferential basis to the following person(s) on receipt of the application money of Rs. 4,49,99,955/- (being the 75% of the issue price).

S.No	Name of Shareholder	Category	No. of Equity Shares
1	Antique Infotech Private Limited	Public	6,81,481
2	Dwight Technologies Private Limited	Public	6,51,851
Total			13,33,332

Consequently, the issued and Subscribed Share Capital of the Company stands increased to Rs. 21,33,32,210/- divided into 2,13,33,221 Equity Shares of Rs.10/- each.

The meeting commenced at 06:30 p.m. and concluded at 07:30 p.m.

This is for your information and records.

Thanking You,

Yours faithfully

**For Vivo Bio Tech Limited**

**A V Kiran**  
**Company Secretary**

Encl. as above

Vivo Bio Tech Limited

03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,

Road No.1, Banjara Hills, Hyderabad-500034

E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163



**UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025**

Rs. in Lacs

S.No.	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Un-Audited	Audited	Un-Audited	Audited
I	Revenue from operations	1,241.86	1,229.07	1,013.42	4,667.25
II	Other Income	13.78	15.31	1.23	480.49
III	<b>Total Income</b>	<b>1,255.64</b>	<b>1,244.38</b>	<b>1,014.65</b>	<b>5,147.74</b>
IV	<b>Expenses</b>				
	a) Increase/(decrease) in stock in trade and WIP	(12.86)	(79.16)	17.21	98.35
	b) Consumption of Raw materials	-	-	-	-
	c) Purchase of traded goods	163.47	156.30	150.56	480.77
	d) Employees Cost	307.35	302.17	233.11	1,185.97
	e) Depreciation and amortisation	264.41	224.57	222.93	901.67
	f) Finance Cost	150.32	168.13	192.44	750.44
	g)Administrative Expenditure	231.35	335.94	174.99	822.42
	<b>Total</b>	<b>1,104.04</b>	<b>1,107.95</b>	<b>991.24</b>	<b>4,239.62</b>
V	<b>Profit Before Tax &amp; Exceptional Items (III-IV)</b>	<b>151.61</b>	<b>136.43</b>	<b>23.41</b>	<b>908.12</b>
	Exceptional Item	-	-	-	-
	Prior Period Items	-	-	-	-
VI	<b>Profit Before Tax</b>	<b>151.61</b>	<b>136.43</b>	<b>23.41</b>	<b>908.12</b>
VII	<b>Tax Expense</b>				
	a. Current Tax	78.97	48.9	19.81	208.28
	b. Deferred tax	(64.69)	(31.03)	(14.19)	(57.24)
	<b>Total Tax Expense</b>	<b>14.29</b>	<b>17.87</b>	<b>5.62</b>	<b>151.04</b>
	<b>VIII Net Profit After Tax (V-VI)</b>	<b>137.32</b>	<b>118.56</b>	<b>17.79</b>	<b>757.08</b>
IX	<b>Other Comprehensive Income</b>				
	a.Items that will be reclassified to profit or loss (Net of Tax)	-	-	-	-
X	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>137.32</b>	<b>118.56</b>	<b>17.79</b>	<b>757.08</b>
XI	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,989.39	1,716.48	1,490.35	1,716.48
XII	Other Equity	-	-	-	5,375.37
XIII	<b>Earnings per equity share:</b>				
	1)Basic	0.76	0.78	0.12	4.95
	2)Diluted	0.76	0.78	0.12	4.95

Place: Hyderabad

Date: August 12, 2025

For Vivo Bio Tech Limited



*Kalyan Ram Mangipudi*  
Kalyan Ram Mangipudi  
Whole Time Director  
DIN: 02012580

Vivo Bio Tech Limited  
03rd Floor, Ilyas Mohammed Khan Estate, 8-2-672/5&6,  
Road No.1, Banjara Hills, Hyderabad-500034  
E-mail:investors@vivobio.com CIN: L65993TG1987PLC007163



UN-AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE, 2025

S.No.	PARTICULARS	QUARTER ENDED			Rs. in Lacs
		30.06.2025	31.03.2025	30.06.2024	YEAR ENDED
		Un-Audited	Audited	Un-Audited	Audited
I	Revenue from operations	1,251.16	1,229.07	1,013.42	4,667.25
II	Other Income	13.78	15.31	1.23	480.49
III	<b>Total Income</b>	<b>1,264.94</b>	<b>1,244.38</b>	<b>1,014.65</b>	<b>5,147.74</b>
IV	<b>Expenses</b>				
	a) Increase/(decrease) in stock in trade and WIP	(12.86)	(79.16)	17.21	98.35
	b) Consumption of Raw materials	-	-	-	-
	c) Purchase of traded goods	163.47	156.30	150.56	480.77
	d) Employees Cost	320.24	314.23	234.25	1,214.46
	e) Depreciation and amortisation	264.41	224.57	222.93	901.67
	f) Finance Cost	150.32	168.13	192.44	750.44
	g)Administrative Expenditure	231.37	336.19	175.00	822.74
	<b>Total</b>	<b>1,116.95</b>	<b>1,120.26</b>	<b>992.39</b>	<b>4,268.43</b>
V	Profit Before Tax & Exceptional Item (III-IV)	<b>147.99</b>	<b>124.12</b>	<b>22.26</b>	<b>879.31</b>
	Exceptional Item	-	-	-	-
	Prior Period Items	-	-	-	-
VI	<b>Profit Before Tax</b>	<b>147.99</b>	<b>124.12</b>	<b>22.26</b>	<b>879.31</b>
VII	<b>Tax Expense</b>				
	a. Current Tax	78.97	48.90	19.81	208.28
	b. Deffered tax	(64.69)	(31.03)	(14.19)	(57.24)
	<b>Total Tax Expense</b>	<b>14.29</b>	<b>17.87</b>	<b>5.62</b>	<b>151.04</b>
	<b>VIII Net Profit After Tax (V-VI)</b>	<b>133.71</b>	<b>106.25</b>	<b>16.64</b>	<b>728.27</b>
IX	Minority Interest	-	-	-	-
X	<b>Other Comprehensive Income</b>				
	a.Items that will be reclassified to profit or loss (Net of Tax)	-	-	-	-
XI	<b>Total other Comprehensive Income(VII+VIII+IX)</b>	<b>133.71</b>	<b>106.25</b>	<b>16.64</b>	<b>728.27</b>
XII	Paid Up Share Capital (Face value of Rs.10/-) (In lakh Units)	1,989.39	1,716.48	1,490.35	1,716.48
XII	Other Equity	-	-	-	5,346.80
XIII	<b>Earnings per equity share:</b>				
	1)Basic	0.74	0.69	0.11	4.76
	2)Diluted	0.74	0.69	0.11	4.76

Place: Hyderabad  
Date: August 12, 2025



For Vivo Bio Tech Limited

*[Signature]*  
Kalyan Ram Mangipudi  
Whole Time Director  
DIN: 02012580

**Notes:**

1. The above Un-Audited Financial Results for the 01<sup>st</sup> Quarter June 30, 2025, are reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 12, 2025.
2. The figures for the quarter ended March 31, 2025 are the balancing figure between the audited figures of the full financial year and the published year-to-date figures upto the 3<sup>rd</sup> quarter of respective financial years which were subject to Limited Review by the Statutory Auditor of the Company.
3. The Un-Audited Financial Results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of Companies Act, 2013 ('The Act') read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
4. The Consolidated Results include results of all subsidiaries, viz., Vivobio Labs Private Limited, Vivobio Discovery Services Private Limited, Surlogic Life Consultancy Private Limited and Vivobio Consulting Services Private Limited (Formerly Donakanti Consulting Services Private Limited).
5. The Company operates in single Segments Viz., Bio Technology. Hence segmental reporting is not required.
6. During the Quarter, the Company has allotted 27,29,073 equity shares pursuant to conversion of warrants issued on preferential basis.
7. The above financial results are available on the stock exchange website [www.bseindia.com](http://www.bseindia.com) and company's website [www.vivobio.com](http://www.vivobio.com).
8. Previous year's/period's figures are rearranged/ regrouped wherever necessary.

**Date: August 12, 2025**  
**Place: Hyderabad**



**For Vivo Bio Tech Limited**

A handwritten signature in black ink, appearing to read "Kalyan Ram Mangipudi".

**Kalyan Ram Mangipudi**  
**Whole Time Director**  
**DIN: 02012580**





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.p murali.com


**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review report to  
The Board of Directors  
Vivo Biotech Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **Vivo Biotech Limited** (the "Company") for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA


Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.p murali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.Murali & Co,  
Chartered Accountants  
FRN: 007257S

  
Mukund Vijayrao Joshi  
Partner

M.No. 024784

UDIN: 25024784BMIXWN9405

Place: Hyderabad

Date: 12-08-2025.





**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com

Website : www.pmurali.com

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended**

**Review report to  
The board of directors  
Vivo Bio Tech Limited**

We have reviewed the accompanying statement of unaudited consolidated financial results of **Vivo Bio Tech Limited** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.







**P. MURALI & CO.,**  
CHARTERED ACCOUNTANTS  
6-3-655/2/3, SOMAJIGUDA,  
HYDERABAD - 500 082. T.G, INDIA

Tel. : (91-40) 2332 6666, 2331 2554  
(91-40) 2339 3967,  
(91-40) 2332 2119, 2331 7032

Email : pmurali.co@gmail.com  
pmurali.tax@gmail.com  
info@pmurali.com  
Website : www.p murali.com


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Vivo Bio Labs Private Limited
2. Vivo Bio Discovery Services Private Limited
3. Surlogic Life Consultancy Private Limited
4. Vivo Bio Consulting Services Private Limited (Formerly known as Donakanti Consultancy Services Private Limited)

Based on our review conducted and procedures performed as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co,  
Chartered Accountants  
FRN: 007257S



Mukund Vijayrao Joshi

Partner

M.No. 024784

UDIN: 25024784BMIXWO7575

Place: Hyderabad

Date: 12-08-2025.